<DOC>
	<DOC>NCT03009513</DOC>
	<brief_summary>An open label, one sequence study to investigate the pharmacokinetic drug interaction between Teneligliptin and Glimepiride in healthy male subjects</brief_summary>
	<brief_title>Teneligliptin-Glimepiride DDI Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>1. Healthy male adult aged 20 to 45 years 2. Body weight â‰¥ 50kg, and BMI between 18 and 29 kg/m2 at screening 3. Subject who agrees to use a medically acceptable doublebarrier method of contraception and not to donate sperms from the first dose until 2 months after the last dose. 4. Subject who was given, and fully understood, the information about the study, and has provided voluntary written informed consent to participate in the study and agreed to comply with the study requirements.</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>